G386-+A mutation in exon 3 that results in a Gly-*Glu change at amino acid 85.
The proband is an 11 year old boy who was first diagnosed as having CF after presenting with a nasal polyp. He has sweat sodium values of 90 mmol/l, mild lung disease, and is pancreatic sufficient. His parents are of Iranian origin and there is a family history of cousin marriages.
Based on predictions from the cDNA sequence of the cystic fibrosis transmembrane conductance regulator (CFTR),' exon 3 of the CF gene would code for part of the amino-terminal cytoplasmic domain heterozygous for G386-+A. The mutation is associated with a pXV2C/KM19 2/1 haplotype. The G85E mutation was first defined by Zielenski et al.'0 The substitution of glutamic acid for glycine at amino acid 85, which would result from the G386-*A mutation, is a relatively major change replacing a polar (uncharged) amino acid with a negatively charged one within the first membrane spanning domain of CFTR and might be expected to have a significant effect on the protein. However, the exceptionally mild disease manifested by the proband would suggest that this amino acid had a minor role in CFTR function. The only other CF patient with this mutation defined to date'0 is of French Canadian origin. This subject has G386-+A in one CF gene and 621 + 1G-+T0 in the other and has classical CF with pancreatic insufficiency (L-C Tsui, personal communication). It would be of interest to compare the severity of phenotype in this subject with CF patients who are homozygous for the 621 + G-4T mutation, since the G85E mutation might be expected to exert a dominant effect in the compound heterozygote. 
